Research programme: diabetes therapy - PhytoMedical Technologies

Drug Profile

Research programme: diabetes therapy - PhytoMedical Technologies

Alternative Names: Cynnamon-derived type A-1 polyphenols - PhytoMedical Technologies

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iowa State University
  • Developer PhytoMedical Technologies
  • Class Polyphenols
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
  • 12 Mar 2007 Data from a clinical study in patients with Type-2 diabetes added to the adverse events and Diabetes therapeutic trials sections
  • 13 Jun 2006 PhytoMedical Technologies and Iowa State University has entered into an exclusive licensing agreement to develop, market and distribute novel synthesised compounds derived from type A-1 polyphenols
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top